Status:

ACTIVE_NOT_RECRUITING

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Lead Sponsor:

Tarsus Pharmaceuticals, Inc.

Conditions:

Meibomian Gland Dysfunction

Demodex Infestation of Eyelid

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demo...

Detailed Description

This is a prospective, randomized controlled, three-arm, investigator- and interpreter-masked study. This study is intended to compare the effect of two dosing regimens of an exploratory vehicle on me...

Eligibility Criteria

Inclusion

  • Key
  • Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
  • Meets all of the following criteria in at least one eye: have more than 10 lashes with collarettes present on the upper lid; have the presence of one or more mites with lash epilation of the upper and lower lids; have evidence of meibomian gland dysfunction; have at least mild erythema of the lower lid; have a tear breakup time of less than 10 seconds; and have intact partial to full meibomian glands in at least 33% of the total meibomian gland area of the lower lid
  • Key

Exclusion

  • Have used lid hygiene products within 7 days of Day 1 or unwilling to forego the use of lid hygiene products during the study
  • Have used systemic antihistamines within 30 days of Day 1
  • Have used artificial eyelashes, eyelash extensions, or had other cosmetic eyelash or eyelid procedures within 7 days of Day 1 or be unwilling to forego their use during the study
  • Contact lens wear within 7 days of Day 1 or unwilling to forego contact lens wear for the duration of the study
  • Be pregnant or lactating at Day 1

Key Trial Info

Start Date :

August 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 15 2024

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT06054217

Start Date

August 1 2023

End Date

June 15 2024

Last Update

April 9 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Shultz Chang Vision

Northridge, California, United States, 91325

2

Vita Eye Clinic

Shelby, North Carolina, United States, 28150